Comparison of serum tumor markers for intrahepatic cholangiocarcinoma and hepatocellular carcinoma

American Surgeon

Volumn 76, Issue 11, 2010, Pages 1210-1213

  Tao, Lian Yuan ^a   Cai, Lei ^a   He, Xiao Dong ^a   Liu, Wei ^a   Qu, Qiang ^a  

^a PEKING UNION MEDICAL COLLEGE HOSPITAL   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA FETOPROTEIN; CA 19-9 ANTIGEN; CA 242 ANTIGEN; CA 50 ANTIGEN; CARCINOEMBRYONIC ANTIGEN;

ADULT; AGED; ARTICLE; BILE DUCT CARCINOMA; CANCER PATIENT; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; FEMALE; HUMAN; INTRAHEPATIC CHOLANGIOCARCINOMA; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; PREOPERATIVE PERIOD; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; SENSITIVITY AND SPECIFICITY;

ADULT; AGED; ALPHA-FETOPROTEINS; ANTIGENS, TUMOR-ASSOCIATED, CARBOHYDRATE; BILE DUCT NEOPLASMS; CA-19-9 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; CARCINOMA, HEPATOCELLULAR; CHI-SQUARE DISTRIBUTION; CHOLANGIOCARCINOMA; DIAGNOSIS, DIFFERENTIAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; LIVER FUNCTION TESTS; LIVER NEOPLASMS; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; SENSITIVITY AND SPECIFICITY; STATISTICS, NONPARAMETRIC; TUMOR MARKERS, BIOLOGICAL;

EID: 78651351867     PISSN: 00031348     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. de Groen PC, Gores GJ, LaRusso NF, et al. Biliary tract cancers. N Engl J Med 1999;341:1368-78.
2. Gatselis NK, Tepetes K, Loukopoulos A, et al. Hepatitis B virus and intrahepatic cholangiocarcinoma. Cancer Invest 2007;25:55-8.
3. Yachimski P, Pratt DS. Cholangiocarcinoma: natural history, treatment, and strategies for surveillance in high-risk patients. J Clin Gastroenterol 2008;42:178-90.
4. Malhi H, Gores GJ. Cholangiocarcinoma: modern advances in understanding a deadly old disease. J Hepatol 2006;45:856-67. (Pubitemid 44646688)
5. Gerhardt T, Milz S, Schepke M, et al. C-reactive protein is a prognostic indicator in patients with perihilar cholangiocarcinoma. World J Gastroenterol 2006;12:5495-500. (Pubitemid 44501808)
6. Li YG, Zhang N. Clinical significance of serum tumour M2-PK and CA19-9 detection in the diagnosis of cholangiocarcinoma. Dig Liver Dis 2009;44:605-8.
7. Briggs CD, Neal CP, Mann CD, et al. Prognostic molecular markers in cholangiocarcinoma: a systematic review. Eur J Cancer 2009;45:33-47.
8. Chen C, Chen LQ, Yang GL, Li Y. Value of tumour markers in diagnosing and monitoring colorectal cancer and strategies for further improvement: analysis of 130 cases. Ai Zheng 2007;26:1221-6.
9. Chen C, Chen LQ, Yang GL, Li Y. The application of C12 biochip in the diagnosis and monitoring of colorectal cancer: Systematic evaluation and suggestion for improvement. J Postgrad Med 2008;54:186-90. (Pubitemid 351975972)
10. Levy M, Visokai V, Lipska L, Topolcan O. Tumour markers in staging and prognosis of colorectal carcinoma. Neoplasma 2008;55:138-42.
11. Ni XG, Bai XF, Mao YL, et al. The clinical value of serum CEA, CA19-9, and CA242 in the diagnosis and prognosis of pancreatic cancer. Eur J Surg Oncol 2005;31:164-9.
12. Takao S, Uchikura K, Yonezawa S, et al. Mucin core protein expression in extrahepatic bile duct carcinoma is associated with metastases to the liver and poor prognosis. Cancer 1999;86:1966-75.
13. Ishikawa K, Sasaki A, Haraguchi N, et al. A case of an alpha-fetoprotein-producing intrahepatic cholangiocarcinoma suggests probable cancer stem cell origin. Oncologist 2007;12:320-4. (Pubitemid 46556798)
14. Shiozawa K, Ishii K, Mori T, et al. Heterochronous development of intrahepatic cholangiocellular carcinoma following hepatocellular carcinoma in a hepatitis B virus carrier. Intern Med 2001;40:624-30. (Pubitemid 33611895)
15. Zhou YM, Yang JM, Li B, et al. Clinicopathologic characteristics of intrahepatic cholangiocarcinoma in patients with positive serum a-fetoprotein. World J Gastroenterol 2008;14:2251-4.
16. Minato H, Nakanuma Y, Terada T. Expression of blood group-related antigens in cholangiocarcinoma in relation to nonneoplastic bile ducts. Histopathology 1996;28:411-9. (Pubitemid 26157688)
17. Haglund C, Lindgren J, Roberts PJ, Nordling S. Difference in tissue expression of tumour markers CA 19-9 and CA 50 in hepatocellular carcinoma and cholangiocarcinoma. Br J Cancer 1991;63:386-9.